LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

Core Viewpoint - LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ, an aceclidine ophthalmic solution, marking a significant step in expanding global access to this treatment for presbyopia [1][3] Group 1: Regulatory Submission and Milestones - The MAA submission to the EMA represents the fifth regulatory submission for VIZZ outside the U.S. [1] - If approved, VIZZ will be available to millions of Europeans suffering from age-related blurry near vision [1][3] - The submission is part of LENZ's strategy to establish VIZZ as a global brand, with ongoing commercialization efforts in various regions including Greater China, South Korea, and the Middle East [3] Group 2: Clinical Data and Efficacy - The MAA is supported by positive results from three Phase 3 CLARITY trials conducted in the U.S., where VIZZ met all primary and secondary endpoints, improving near vision within 30 minutes and lasting up to 10 hours [2] - VIZZ was well tolerated, with no serious treatment-related adverse events reported over 30,000 treatment days across the trials [2] Group 3: Market Opportunity and Company Strategy - Presbyopia affects approximately 1.8 billion people globally, with Europe being a significant market for vision correction products [3] - The company aims to pursue commercialization in Europe through strategic partnerships, complementing existing partnerships in other regions [3][4]